Senate strips drug transparency bill of key safety provisions
The Clear Labels Act loses its unique identifier requirement and gets a five-year compliance timeline, drawing criticism from safety experts.
What to know
- The Clear Labels Act, designed to reveal drug manufacturing locations to consumers and doctors, has lost its most powerful enforcement mechanism—a unique FDA factory identifier—just before a Senate vote.
- Implementation timeline extended from one year to five years; safety experts argue this delay significantly weakens transparency effectiveness.
- Lawmakers cited rising drug prices and national security concerns as reasons for the changes, while sponsors still frame the bill as a 'massive win' despite the concessions.
“The unique identifier requirement has been removed from the bill, and the timeline for companies to come into compliance was extended to five years.”
ProPublica, Investigative newsroom · ProPublica ↗
Sen. Rick Scott Bill sponsor
Sen. Kirsten Gillibrand Bill sponsorRetired Army Col. Vic Suarez Former medical supply-chain commanderDr. Kevin Schulman Stanford professor of medicine and health policyPeter Baker Former FDA inspector
How it unfolded 2 developments, newest first · click a bar or a number to jump articlesposts
-
1
Safety experts and former FDA inspector criticize the weakened bill
Dr. Kevin Schulman and other experts argue the five-year delay undermines the bill's effectiveness, while Sens. Scott and Gillibrand defend the changes as necessary for FDA rulemaking and manufacturer compliance, though they call it a 'massive win for consumer safety and transparency.'
“Five years after it passes might as well be a lifetime.”
— Dr. Kevin Schulman -
P
NEW: The Clear Labels Act was designed to help patients and doctors see exactly where a medication was made. But experts say the law’s most critical provisions have been cut: “It's just a clear watering down of the original bill.”
2 more of the top 3 · 5 posts in this stretch
-
C
https://www. propublica.org/article/clear-l abels-act-drug-safety-senate-vote
-
The Clear Labels Act was designed to alert consumers to where their drugs are coming from. After two major changes to the bill, experts worry it won’t be as effective.
-
-
2
Senate removes FDA identifier requirement and extends compliance timeline
Senators strike two critical provisions from the bill: the unique FDA factory identification code that would enable tracking of facility regulatory histories, and the one-year implementation deadline, replacing it with a five-year timeline. Lawmakers cited concerns that the requirements would raise drug prices and compromise national security.
“It's just a clear watering down of the original bill.”
— Retired Army Col. Vic Suarez -
background
Senators Scott and Gillibrand introduce Clear Labels Act — The bipartisan bill is introduced to require drug labels to disclose exactly where medications are manufactured, addressing transparency gaps that had kept manufacturing details hidden even from Congress.
-
background
ProPublica exposes unsafe foreign drug manufacturing in U.S. supply chain — ProPublica investigation reveals the U.S. continued importing generic drugs from foreign factories with documented quality and safety lapses, including leaks, mold, and contaminated water. Medications from these facilities were linked to thousands of reported adverse reactions in patients.
What people are saying 1 voices from 1 site · best of 5 · verbatim
- Sep 18
-
L
"You don't get to know if your meds are made in a contaminated factory because it might harm national security" is a new one. This is a great read (in a series of great reads from @propublica.org on this topic) from Naisha Roy.